ISSN 1662-4009 (online)

ey0021.12-16 | Lipid Metabolism | ESPEYB21

12.16. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia

A Wiegman , S Greber-Platzer , S Ali , MD Reijman , EA Brinton , MJ Charng , S Srinivasan , C Baker-Smith , S Baum , JA Brothers , J Hartz , PM Moriarty , J Mendell , S Bihorel , P Banerjee , RT George , B Hirshberg , R Pordy

Homozygous familial hypercholesterolemia (HoFH) is a severe disorder caused by genetic mutations in LDLR (encoding the LDL receptor), APOB or PCSK9. LDL-C levels in HoFH are extremely elevated)>400 mg/dL(even in utero, leading to cardiovascular events, and disability or death during childhood and adolescence. Conventional medications have minimal efficacy, since LDL-C levels cannot be reduced through upregulation of hepatic LDL receptors.<p c...

ey0020.10-12 | Dyslipidemia | ESPEYB20

10.12. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients

SE Nissen , AM Lincoff , D Brennan , KK Ray , D Mason , JJP Kastelein , PD Thompson , P Libby , L Cho , J Plutzky , HE Bays , PM Moriarty , V Menon , DE Grobbee , MJ Louie , CF Chen , N Li , L Bloedon , P Robinson , M Horner , WJ Sasiela , J McCluskey , D Davey , P Fajardo-Campos , P Petrovic , J Fedacko , W Zmuda , Y Lukyanov , SJ Nicholls , CLEAR Outcomes Investigators Nicholls

Brief summary: In this double-blind, randomized, placebo-controlled trial, bempedoic acid (Nexletol) reduced the incidence of a composite cardiovascular.Comment: Bempedoic acid is an ATP citrate lyase inhibitor. ATP citrate lyase catalyses the conversion of citrate to acetyl-CoA, the fundamental substrate required for the synthesis of cholesterol and fatty acids. By inhibiting the cholesterol synthesis pathway, bempedoic acid reduces intra-hepatic LDL-C....